通过使用大型行政索赔数据库,确定美国遗传性血管发症的患病率
Anthony J Castaldo1, Karen E Wells2, Subhan Khalid2
1US Hereditary Angioedema Association (HAEA), Fairfax, Virginia.
概括
这项研究使用保险索赔数据为所有遗传性血管 (HAE) 类型提供了美国第一个流行率估计. 调查结果显示,患病率高于之前所述,影响了患者数量和治疗策略.
科学领域:
- 医学研究 医学研究
- 流行病学 流行病学
- 遗传学 是一个遗传学.
背景情况:
- 遗传性血管 (HAE) 是一种罕见的,危及生命的遗传性疾病,在美国的患病率尚不清楚.
- 最近批准的HAE疗法增加了患者数量和索赔数据的可用性.
研究的目的:
- 用保险索赔数据估计所有类型遗传性血管 (HAE) 的美国患病率.
- 为了建立一个全面的,现实世界的HAE在美国的流行率数字.
主要方法:
- 对IQVIA的PharMetrics Plus MedTech索赔数据库 (2018-2020) 的回顾性分析.
- 开发了一个使用ICD-10代码用于血管神经或补体系统缺陷以及HAE药物要求的代理算法.
- 专家小组审查了汇总数据;敏感性分析调整为医疗保险患者代表性不足.
主要成果:
- 每年未经调整的HAE患病率估计在每10万人中从2.67到2.43不等.
- 专家医生分析得出患病率估计为每10万人中2.13至1.84.
- 这些数字超过了通常引用的C1抑制剂缺乏HAE的2:100,000患病率.
结论:
- 这项研究为所有HAE类型提供了第一个基于索赔的全面美国流行率估计.
- 这些发现提供了HAE的现实预测流行率,涵盖所有亚型.
- 结果表明,HAE患病率可能比以前理解的要高.
相关概念视频
01:11Genome-wide Association Studies-GWAS
14.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
527
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
527